A New TR-FRET Assay Platform: THUNDER™
Time-Resolved FRET (TR-FRET) is a well-established technology widely used in drug discovery and clinical diagnostics, and increasingly a highly versatile assay technology for studying biological interactions from low to high affinity, using both small and large molecules.
This webcast, presented by BioAuxilium, introduces the THUNDER™ TR-FRET assay platform.
Speaker
Jaime Padros, PhD
President | BioAuxilium Research
Dr. Jaime Padros is the co-founder and President of BioAuxilium Research, a Canadian biotech specialized in drug discovery assay kits and reagents based on the THUNDER™ TR-FRET technology. He has 25 years of experience developing and optimizing biochemical and cell-based assays for high-throughput screening. Before BioAuxilium, he led the design and development of drug discovery assay kits and reagents at PerkinElmer Bio-discovery (now Revvity), including the LANCE® Ultra TR-FRET portfolio.
Key Learning Objectives
- Overview of the THUNDER™ TR-FRET assay platform
- Advantages of THUNDER™ over traditional TR-FRET platforms
- Phospho-protein detection in cell lysates with THUNDER™
- Biomarker detection in cell supernatants with THUNDER™
- The THUNDER™ cAMP Assay Kit
- BioAuxilium’s validation process
Watch Now: A New TR-FRET Assay Platform: THUNDER™
This webinar is available on demand. Fill in the form to watch the full recording — we'll email you the link too.
- June 27, 2024
- Jaime Padros, PhD, BioAuxilium Research
- kbiinfo@krishgen.com
- +91 22 49198700
Your details
Request the recording
Fill in your details and you'll go straight to the recording — we'll also email you the link.
More Webinars
Shortcuts to Discovery and Characterization of Monoclonal Antibodies
Monoclonal antibody (mAb) discovery and characterization often face significant delays due to iterative screening cycles, late-stage functional failures, and downstream analytical bottlenecks. This webinar details five practical shortcuts that accelerate timelines from target validation to preclinical characterization.
View Webinar June 12, 2026Viral Vectors & CRISPR for Building Disease Models
Gene editing and viral vector technologies are transforming the development of advanced disease models for translational research.
View Webinar April 17, 2026Advanced Immunocompetent Primary Human Airway Models for Respiratory Disease Modeling
Advancements in human-relevant in vitro models are transforming how respiratory diseases are studied and how drug safety and efficacy are evaluated.
View Webinar